Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(TWA-0804) Fc glycan composition in human immunity Therapeutic Area


 Return to List of Clinical Studies
 Return to List of Protocols for Healthy Volunteers
An open label study of IgG Fc glycan composition in human immunity Therapeutic Area

Principal Investigator:
Taia Wang

Investigators:

Contact Information:
Clinical Research Support Office The Rockefeller University
1230 York Ave
New York, NY 10065
Telephone: 18007822737
Alt. Telephone: 18007822737
Email: rucares@rockefeller.edu
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
Antibodies are principle mediators of immunity against infections and they can also give rise to autoimmune and inflammatory diseases. Two functional domains make up an IgG antibody – the Fab domain binds to a specific target, while the Fc domain can interact with receptor molecules to activate a pro- or anti- inflammatory state. The Fc domain of IgGs contains a glycan that is variable in composition and its specific sugar components are an important determinant of the biologic activity of IgGs in both protective and pathologic immune responses. New disease treatments could be developed through purposeful manipulation of IgG Fc glycans, but there is currently little known about how Fc glycan composition is regulated. We plan to study this by evaluating whether vaccination can cause changes in Fc glycan composition and, if so, whether signaling from helper T cells, age of the patient, and/or route of vaccine administration are determinants of specific modifications that are triggered by vaccination. Next, we will study effects that specific components within the Fc glycan have on immunity against the common human pathogens Streptococcus pneumoniae and influenza viruses using in vitro and in vivo models of infection.



Detailed Description of Protocol:




What specifically makes a person eligible for the study?
You may be eligible to enter this study:

18-80 years of age Willing to receive a single dose of an FDA approved vaccine available for 7 visits over a 12 week time period

Gender:
Both

Age(s):
18-80

Children permitted to participate:
No

Potential Benefits.....




Compensation:
Compensation is provided